Experience of using Rituximab in neurological practice (literature review and own observation)
Open Access
- 27 November 2021
- journal article
- research article
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 28 (2) , 17-22
Abstract
Currently, due to the lack of specific etiotropic therapy, rituximab is widely used for the treatment of most autoimmune diseases of the central and peripheral nervous system. Rituximab is a chimeric monoclonal antibody with specificity for CD20, the antigen found on the surface of normal and malignant B-lymphocytes. It is used mainly in hematological practice. It is used off-label for the treatment of neurological diseases. The world literature describes the use of rituximab for the treatment of such pathologies as autoimmune encephalitis, neuromyelitis optica spectrum disorder, multiple sclerosis, primary angiitis of the central nervous system, immune-mediated inflammatory polyneuropathy, myasthenia gravis, refractory to basic immunosuppressive therapy. This article provides an overview of the world literature on the use of rituximab in neurological practice, describes our own experience of its use on the basis of the Department of Neurology № 1 of Pavlov University (Saint Petersburg, Russia).Keywords
This publication has 14 references indexed in Scilit:
- Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyCochrane Database of Systematic Reviews, 2017
- Neuromyelitis Spectrum DisordersMayo Clinic Proceedings, 2017
- International consensus guidance for management of myasthenia gravisNeurology, 2016
- Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesDrugs, 2016
- The Diagnosis and Treatment of Autoimmune EncephalitisJournal of Clinical Neurology, 2016
- Positive experience of the usage of Rituximab in management of refractory myasthenia gravis in RussiaNeuromuscular Diseases, 2015
- OPPORTUNITIES OF ANTI B-CELL THERAPY IN MULTIPLE SCLEROSISMedical Immunology (Russia), 2014
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revisionJournal of the Peripheral Nervous System, 2010
- Practical considerations on the use of rituximab in autoimmune neurological disordersTherapeutic Advances in Neurological Disorders, 2010
- Motor-dominant chronic inflammatory demyelinating polyneuropathyJournal of Neurology, 2009